Tuesday, October 20, 2009: 2:00 PM-4:00 PM
204 B (Pennsylvania Convention Center)
| Moderator: |
Susan Manzi, MD, MPH, University of Pittsburgh
|
2:30 PM
Belimumab, a BLyS-Specific Inhibitor, Reduced Disease Activity, Flares and Prednisone Use in Patients with Active SLE: Efficacy and Safety Results From the Phase 3 BLISS-52 Study
S. Navarra1, R. Guzman2, A. Gallacher3, R.A. Levy4, E.K. Li5, M. Thomas6, R. Jimenez7, M. Leon8, S. Hall9, J.L. Lan10, E. Nasonov11, C. Tanasescu12, H.-Y. Kim13, L. Pineda14, Z.J. Zhong14, W. Freimuth14, M. A. Petri15 and BLISS-52 Study Group, 1U of Sto Tomas Hosp, Mla, Philippines, Mla, Philippines, 2Bogota, Colombia, 3HBBA, Buenos Aires, Argentina, 4Univ do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 5Chinese U of HK, Hong Kong, China, 6Kerala Inst of Med Sci, Trivandrum, India, 7Hosp Dr Gustavo Fricke, Vina del Mar, Chile, 8Inst de Ginec y Rep, Lima, Peru, 9Emeritus Res-Cabrini Hosp, Malvern, Australia, 10Veterans Gen Hosp, Taiching, Taiwan, 11Institute of Rheumatology, Moscow, Russia, 12Spitalul Clin Colentina, Bucharest, Romania, 13Catholic U of Korea St Mary's Hosp, Seoul, South Korea, 14HGS, Rockville, MD, 15Johns Hopkins U, Baltimore, MD
2:45 PM
Treatment of Rheumatoid Arthritis (RA) with An Oral Syk Kinase Inhibitor: A 6 Month Randomized Placebo Controlled Phase 2b Study in Patients with Active RA On Chronic Methotrexate
Michael Weinblatt1, Arthur Kavanaugh2, Mark Genovese3, Elliott Grossbard4 and Daniel Magilavy4, 1Brigham & Women's Hosp, Boston, MA, 2UCSD, San Diego, CA, 3Stanford University, Palo Alto, CA, 4Rigel Pharma, South San Francisco, CA
3:00 PM
An Oral Syk Kinase Inhibitor in the Treatment of Rheumatoid Arthritis(RA): A 3 Month Randomized Placebo Controlled Phase 2 Study in Patients with Active RA Who Had Failed Biologic Agents
Mark C. Genovese, Stanford University, Palo Alto, CA, Arthur Kavanaugh, UCSD, San Diego, CA, Charles Peterfy, SYNARC, Inc, San Francisco, CA and Daniel Magilavy, Rigel Pharmaceuticals, South San Francisco, CA
3:15 PM
Canakinumab (ACZ885) Vs. Triamcinolone Acetonide for Treatment of Acute Flares and Prevention of Recurrent Flares in Gouty Arthritis Patients Refractory to or Contraindicated to NSAIDs and/or Colchicine
Alexander So1, Marc De Meulemeester2, Talha Shamim3, Andrey Pikhlak4, A. Eftal Yücel5, Udayasankar Arulmani6, Dominik Richard6, Valda Murphy6, Peter Sallstig6 and Naomi Schlesinger7, 1CHU Vaudois, University of Lausanne, Lausanne, Switzerland, 2Gozee, Belgium, 3Heartland Clinical Research, Omaha, NE, 4Moscow State University of Medicine and Dentistry, Moscow, Russia, 5Baskent University, Ankara, Turkey, 6Novartis Pharma AG, Basel, Switzerland, 7UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
3:30 PM
Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results From the GO-REVEAL Study
A. Kavanaugh1, D. van der Heijde2, D. Gladman3, P. Mease4, I. McInnes5, G.G. Krueger6, W. Xu7, M. U. Rahman8, J. Zrubek7, A. Baratelle7 and A. Beutler7, 1University of California at San Diego, San Diego, CA, 2Leiden U Med Ctr, Leiden, Netherlands, 3Toronto Western Hosp, Toronto, ON, 4Swedish Med Ctr/U of Washington, Seattle, WA, 5U of Glasgow, Glasgow, United Kingdom, 6U of Utah Hlth Sciences Ctr, Salt Lake City, UT, 7Centocor R&D, Inc, Malvern, PA, 8Centocor R&D, Inc/U of Penn School of Med, Malvern, PA
3:45 PM
In Early RA with Insufficient Response to MTX, the Addition of Anti-TNF Results in Less Radiological Progression Over 24 Months Than the Addition of Conventional DMARDs: Results From the SWEFOT Trial
Ronald F. van Vollenhoven, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden, Kristina Albertsson, Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Kristina Forslind, Department of Rheumatology, Helsingborgs Hospital, Helsingborg, Sweden, P. Geborek, Dept of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden, Sofia Ernestam, Karolinska University Hospital, Stockholm, Sweden, Ingemar F. Petersson, Musculoskeletal Research Center, Lund, Sweden, Johan Bratt, Karolinska Univ Hosp Huddinge, Stockholm and SWEFOT study group, Sweden
![[ Visit Client Website ]](images/banner.gif)